Vertex Says FDA Will Rule on Telaprevir By May

[Guest guest]

Vertex Says FDA Will Rule on Telaprevir By May

Associated Press - Jan. 20, 2011

Vertex Pharmaceuticals said Thursday that regulators in the U.S. and Canada will

speed their reviews of its drug candidate telaprevir, meaning the hepatitis C

therapy could be approved months earlier than usual. Vertex said the FDA will do

a six-month priority review on telaprevir, meaning the agency expects to make a

decision by May 23. Typical FDA reviews last about 10 months, starting from the

date the drug maker files for approval.